Fragmin Clears FDA For VTE In Cancer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears Pfizer/Eisai’s low molecular weight heparin following oncology panel’s unanimous recommendation for approval.
You may also be interested in...
Sanofi-Aventis’ Semuloparin May Have Safety Advantage For ODAC To Consider
Unlike Pfizer and Eisai’s Fragmin (dalteparin), the new ultra-low-molecular-weight heparin does not appear to carry a hematoma risk.
Pfizer’s Antithrombotic Fragmin Recommended For Use In Cancer Patients
FDA's Oncologic Drugs Advisory Committee unanimously recommended approval of an sNDA for Pfizer's low molecular weight heparin Fragmin for treatment and prevention of venous thromboembolism in cancer patients
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.